ADARx Pharmaceuticals $ADRX

· NASDAQ

$12.79
-1.37 (-9.68%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 20, 2026, the first target we tracked for ADRX.

ADARx Pharmaceuticals (ADRX) is trading down at $12.79 (-9.68%) on NASDAQ, as of the latest quote. It operates in the sector.

IPO: September 25, 2026 · $17.00 offering · Nasdaq

Analyst price targets on ADRX

One firm's current price target on ADARx Pharmaceuticals: $32 — 150% above the current $12.8. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 20, 2026 FirmMorgan Stanley RatingOverweight · initiates Targetat $17.7 · $32 +81% Horizonby Oct 2027 StatusOpen

Entry price $17.7, the close nearest Oct 20, 2026, when the target was reported; the target is +81% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 20, 2027.

Source Morgan Stanley initiates ADARx stock with overweight rating Investing.com · Oct 20, 2026 · opens the publisher's site
with an overweight rating and a price target of $32.00

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

ADARx Pharmaceuticals revenue & net income history

RevenueNet incomeNet margin (right axis, %)
$2.22M−$12.9M−$28.1MQ1 FY2027 net income: −$25.8MQ1 '27Q2 FY2027 revenue: $2.22MQ2 FY2027 net income: −$28.1M · Net margin −1268.2%Q2 '27−100%−75%−50%−25%0%Q2 FY2027 net margin: −1268.2% (off the scale, which stops at −100.0%)
ADARx Pharmaceuticals quarterly financial statements
Q1 FY27Jun 2026Q2 FY27Sep 2026
Income statement
Revenue—$2.22M
Operating income—−$32.2M
Operating margin—−1451.4%
Net income−$25.8M−$28.1M
Net margin—−1268.2%
EPS (diluted)—−$1.74
Balance sheet
Cash and equivalents—$570.6M
Total assets—$929.1M
Total liabilities—$354.7M
Shareholders' equity−$251.1M$574.4M

From ADARx Pharmaceuticals's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →

ADARx Pharmaceuticals in the news

Nov 9, 2026 GlobeNewswire ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
Sep 17, 2026 PR Newswire Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight